Not FDA-Approved (Reclassification Pending)Growth Hormone

Ipamorelin

Also known as: Ipamorelin Acetate

One of the most selective growth hormone secretagogues available. It triggers GH release from the pituitary without significantly raising cortisol or prolactin, which makes it cleaner than older GH peptides like GHRP-6. Previously restricted from compounding but expected to return to legal status in 2026.

How it works

Ipamorelin works by mimicking ghrelin, the hunger hormone, at the growth hormone secretagogue receptor (GHS-R) in the pituitary gland. But unlike ghrelin or GHRP-6, ipamorelin is highly selective. It triggers a clean GH pulse without the big cortisol or prolactin spikes you see with less selective GH peptides. This is why it's so popular as a standalone or paired with CJC-1295.

Common uses

Side effects

Key research

Safety notes

  • Not FDA-approved for any therapeutic use
  • Was placed on FDA Category 2 restricted list in 2023-2024
  • Among the 14 peptides expected to return to Category 1 per HHS announcement in February 2026, pending formal FDA publication
  • Requires monitoring of IGF-1 levels
  • Not appropriate for individuals with active cancer

Too many clinics, not enough clarity?

We don't sell peptides. Tell us your goals and we'll connect you with a vetted provider who can figure out what actually makes sense for you.

See what's right for you

Explore other peptides